Chiaki Wakasa-Morimoto

<i>In Vitro</i>Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

Masanori Kobayashi, Tomokazu Yoshinaga, Takahiro Seki et al. · Antimicrobial Agents and Chemotherapy · 2010 · 377 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacology +17

Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection

Tomokazu Yoshinaga, Masanori Kobayashi, Takahiro Seki et al. · Antimicrobial Agents and Chemotherapy · 2014 · 100 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacology +17

The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral

Edward P. Garvey, Brian A. Johns, Margaret Gartland et al. · Antimicrobial Agents and Chemotherapy · 2007 · 76 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics

Koichiro Nakahara, Chiaki Wakasa-Morimoto, Masanori Kobayashi et al. · Antiviral Research · 2008 · 50 citations

Life Sciences, Microbiology, Molecular Biology +17

Effects of Raltegravir or Elvitegravir Resistance Signature Mutations on the Barrier to Dolutegravir Resistance <i>In Vitro</i>

Takahiro Seki, Akemi Suyama-Kagitani, Shinobu Kawauchi-Miki et al. · Antimicrobial Agents and Chemotherapy · 2015 · 41 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +17